GB1015956A - Process for the preparation of a new medicament - Google Patents
Process for the preparation of a new medicamentInfo
- Publication number
- GB1015956A GB1015956A GB28500/63A GB2850063A GB1015956A GB 1015956 A GB1015956 A GB 1015956A GB 28500/63 A GB28500/63 A GB 28500/63A GB 2850063 A GB2850063 A GB 2850063A GB 1015956 A GB1015956 A GB 1015956A
- Authority
- GB
- United Kingdom
- Prior art keywords
- cultures
- escherichia coli
- hours
- culture
- autolysate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1735—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A medicament useful in the treatment of affections of the gastro-intestinal tract is prepared by culturing separately, on milk containing gastropyloric mucin of the pig, lysine, arginine and histidine, Lactobacillus acidophilus and non-pathogenic Escherichia coli, and either lyophilizing and then mixing the cultures, or first mixing the cultures, keeping the mixture until it is free from histamine, for example for between 12 and 24 hours, and finally lyophilizing. Medicaments containing 50-150 mg. lyophilized culture of Lactobacillus acidophilus and 50-150 mg. of an equal mixture of the lyophilized cultures of two strains of Escherichia coli together with 20-50 mg. of a lyophilized culture of Bifidibacterium bifidus and (unspecified) amounts of streptogenin in the form of an enzymatic autolysate of fish liver or casein and of other factors, may be bound up in a gelatine capsule; when the enzymatic autolysate is a hygroscopic powder, it is presented separately. The Lactobacillus acidophilus is cultivated in a medium consisting of 950 ml. sterilized skimmed milk, 50 ml. of a 1% aqueous solution of pig's gastro pyloric mucin (containing 1-2.5% of solids) which is obtained by subjecting a mixture of red mucous and pyloric antrum of the pig to extraction with an aqueous solution of caustic soda, 0.5 gram each of lysine, arginine and histidine, 5 micrograms of crystalline Vitamin B12 and minor amounts of specified antibiotics. When it has acquired resistance to antibiotics, the ferment is seeded on a similar culture medium containing no antibiotic; before the seeding, the culture medium is sterilized by treating twice at 100 DEG C. with an interval of 24 hours between heating periods. After seeding, the medium is incubated at 41 DEG C. until a homogeneous curdled product is obtained, which takes about 24 hours. The curd may then be directly frozen, for example at -60 DEG C., and lyophilized. Before freezing the lactic acidity may be neutralized to pH 6.5 with trisodium phosphate solution. Non-pathogenic strains of Escherichia coli which acidify lactose-containing media in less than 24 hours, give indole, do not grow on a disclosed medium containing citrate, are free from haemolysins active against red corpuscles and show the greatest resistance to common antibiotics, are preferred. Two different strains of Escherichia coli are separately cultivated in successive mixtures of the above-described culture medium with decreasing amounts of peptone-containing water consisting of 15 grams peptone, 5 grams sodium chloride and 1 gram of lactose per litre.ALSO:A medicament useful in the treatment of affections of the gastro-intestinal tract is prepared by culturing separately, on milk containing gastropyloric mucin of the pig, lysine, arginine and histidine, Lacto bacillus acidophilus and non-pathogenic Escherichia coli, and either lyophilising and then mixing the cultures, of first mixing the cultures, keeping the mixture until it is free from histamine, for example for between 12 and 24 hours, and finally lyophilising. Medicaments containing 50-150 mg. lyophilised culture of Lactobacillus acidophilus and 50-150mg. of an equal mixture of the lyophilised cultures of two strains of Escherichia coli together with 20-50mg. of a lyophilised culture of Bifidibacterium bifidus and (unspecified) amounts of strepogenin in the form of an enzymatic autolysate of fish liver or casein and of other farters may be bound up in a gelatine capsule; when the enzymatic autolysate is hygroscopic powder, it is presented separately. The medicament may be administered to infants and adults in the treatment of gastro-intestinal infections in general, may receiving particular mention, notably gastroenteritis and colitis, and to pigs, immediately they are born, to reduce their rate of mortality.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR904533A FR2427M (en) | 1962-07-19 | 1962-07-19 | Bacteriotherapeutic drug, in particular for the treatment of gastrointestinal disorders. |
FR939081 | 1963-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1015956A true GB1015956A (en) | 1966-01-05 |
Family
ID=26196723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB28500/63A Expired GB1015956A (en) | 1962-07-19 | 1963-07-18 | Process for the preparation of a new medicament |
Country Status (4)
Country | Link |
---|---|
CH (1) | CH423096A (en) |
DK (1) | DK108015C (en) |
GB (1) | GB1015956A (en) |
LU (1) | LU44002A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61280433A (en) * | 1985-04-17 | 1986-12-11 | ヴァリオ・リミテッド | Acidophilus strain culture, isolation and therapy by same bacteria |
US4689226A (en) * | 1980-01-11 | 1987-08-25 | Farmos-Yhtyma Oy | Process for the production of a bacterial preparation for the prophylaxis of intestinal disturbances in poultry |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS587297B2 (en) * | 1976-05-21 | 1983-02-09 | 秦 興世 | Deodorizers and their manufacturing and storage methods |
-
1963
- 1963-07-03 LU LU44002D patent/LU44002A1/xx unknown
- 1963-07-05 CH CH844263A patent/CH423096A/en unknown
- 1963-07-18 DK DK344463AA patent/DK108015C/en active
- 1963-07-18 GB GB28500/63A patent/GB1015956A/en not_active Expired
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4689226A (en) * | 1980-01-11 | 1987-08-25 | Farmos-Yhtyma Oy | Process for the production of a bacterial preparation for the prophylaxis of intestinal disturbances in poultry |
JPS61280433A (en) * | 1985-04-17 | 1986-12-11 | ヴァリオ・リミテッド | Acidophilus strain culture, isolation and therapy by same bacteria |
JPH0648979B2 (en) | 1985-04-17 | 1994-06-29 | ヴァリオ・リミテッド | Acidophilus strain culture, method for isolating the strain and method for treating the strain with bacteria |
Also Published As
Publication number | Publication date |
---|---|
DK108015C (en) | 1967-07-31 |
CH423096A (en) | 1966-10-31 |
LU44002A1 (en) | 1963-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3320130A (en) | Medicament for colitis, gastroenteritis and enterocolitis | |
TAMURA | Nutriology of bifidobacteria | |
Hove et al. | Lactic acid bacteria and the human gastrointestinal tract | |
Tamime et al. | Microbiological and technological aspects of milks fermented by bifidobacteria | |
EP0833644B1 (en) | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders | |
MacGillivray et al. | Use of lactulose to create a preponderance of lactobacilli in the intestine of bottle-fed infants | |
EP0555618B1 (en) | Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria | |
EP1162987B1 (en) | Pharmaceutical composition for medical and veterinary use for regenerating intestinal flora in diarrhoea or dyspeptic syndrome | |
US6156320A (en) | Fermented milk nutraceuticals | |
CN101460181A (en) | Prevention and treatment of otitis media with non-pathogenic bacterial strains | |
Gonzalez et al. | Biotherapeutic role of fermented milk | |
US6358521B1 (en) | Fermented milk nutraceuticals | |
JPH10309178A (en) | Antiallergic agent and fermented food containing bifidus bacterium as active component | |
JP2532911B2 (en) | Composition for promoting intestinal colonization of useful bacteria | |
GB1015956A (en) | Process for the preparation of a new medicament | |
CN107427461B (en) | Method for activating lactic acid bacteria | |
JP3149403B2 (en) | Bifidobacterium oligosaccharide utilization improver | |
US8007783B2 (en) | Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine | |
KR102452957B1 (en) | Composition for preventing or treating clostridioides difficile infection comprising combination of probiotics | |
US20050215471A1 (en) | Compositions of bacteria and alpha-lactalbumin and uses thereof | |
JP3587536B2 (en) | Calcium reinforcing agent and method for producing the same | |
JP2018062491A (en) | Composition for inhibiting intestinal decrease of lactobacillus lactic acid bacteria counts | |
JP3390613B2 (en) | Bifidus factor activity enhancer / stabilizer | |
JPS60188060A (en) | Live mold powder of bacterium belonging to genus bifidobacterium, having high resistance to acid in stomach, and its preparation | |
RU2018313C1 (en) | Method for producing probiotics for animals and poultry |